Yoshiko Urata

Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L

Yoshiko Urata, Nobuyuki Katakami, Satoshi Morita et al. · Journal of Clinical Oncology · 2016 · 154 citations

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

Miyako Satouchi, Shunichi Negoro, Yasuhiro Funada et al. · British Journal of Cancer · 2007 · 48 citations · Full text

Tobacco Control, Oncology, Cancer Risk +14

Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (<scp>W</scp>est <scp>J</scp>apan <scp>O</scp>ncology <scp>G</scp>roup 5910L): An open‐label, randomized, phase 2 trial

Masayuki Takeda, Takeharu Yamanaka, Takashi Seto et al. · Cancer · 2016 · 41 citations · Full text

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Motoko Tachihara, Shunichi Negoro, Takako Inoue et al. · BMC Cancer · 2018 · 38 citations · Full text

Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer

Yuichiro Yasuda, Yoshiko Urata, Rie Tohnai et al. · Internal Medicine · 2017 · 35 citations · Full text

Immune-related Colitis Induced, Dysbiosis, Lung Inflammation +17